6-Bromo-3'-nitroflavone, a new high affinity benzodiazepine receptor agonist recognizes two populations of cerebral cortical binding sites

Bioorganic and Medicinal Chemistry Letters

Volumn 7, Issue 3, 1997, Pages 373-378

  Viola, Haydee ^a   Marder, Mariel ^b   Wolfman, Claudia ^a   Wasowski, Cristina ^b   Medina, Jorge H ^a   Paladini, Alejandro C ^b  

^a Facultad de Medicina   (Argentina)

^b Instituto de Quimica y Fisicoquimica Biologicas Buenos Aires   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 6 BROMO 3' NITROFLAVONE; BENZODIAZEPINE RECEPTOR; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; DIAZEPAM; FLUNITRAZEPAM; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG; ZOLPIDEM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; BRAIN CORTEX; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DRUG RECEPTOR BINDING; HIPPOCAMPUS; IN VITRO STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; RAT; SPINAL CORD; TRANQUILIZING ACTIVITY;

EID: 0031552094     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(97)00020-6     Document Type: Article

References (16)

1. 1. Medina, J. H.; Paladini, A. C.; Levi de Stein, M.; Calvo, D., Diaz, L. E.; Peña, C. Biochem. Pharmacol. 1990, 40, 2227.
2. 2 Wolfman, C.; Viola, H.; Paladini, A. C.; Dajas, F; Medina, J. H. Pharmacol. Biochem. Behav. 1994, 47, 1.
3. 3 Viola, H.; Wasowski, C.; Levi de Stein, M.; Wolfman, C.; Silveira, R; Dajas, F.; Medina, J. H.; Paladini, A. C. Planta Medica 1995, 61, 213.
4. 4. Marder, M.; Viola, H.; Wasowski, C.; Wolfman, C.; Waterman, P.; Medina, J. H.; Paladini, A. C. Bioorg. Med. Chem. Lett. 1995, 5, 2717.
5. 5. Marder, M.; Viola, H.; Wasowski, C.; Wolfman, C.; Waterman, P.; Cassels, B. K.; Medina, J. H.; Paladini, A. C. Biochem. Biophys. Res. Commun. 1996, 223, 384.
6. 6. Klepner, C. A.; Lippa, A. S.; Benson, D. I.; Sano, M. C.; Beer, B. Pharmacol. Biochem. Behav. 1979, 11, 457.
7. 7. Arbilla, S.; Allen, J.; Wick, A.; Langer, S. Z. Eur. J. Pharmacol. 1986, 130, 257.
8. 8 Sieghart, W. Trends Pharmacol. Sci. 1992, 13, 446.
9. 9. Doble, A.; Martin, I. L. Trends Pharmacol. Sci. 1992, 13, 76.
10. 10. Wisden, W.; Laurie, D. J.; Monyer, H.; Seeburg, P. J. Neurosci. 1992, 12, 1040.
11. 11. McKernan, R. M.; Whiting, P. J. Trends Neurosci. 1996, 9, 139.
12. 3) δ 8.37 (d, J = 2.4 Hz, H-5), 8.11 (dd, J = 1.5, 7.7 Hz, H-6′), 7.75 (m, H-7, H-3′, H-4′, H-5′), 7.29 (d, J = 9.0 Hz, H-8), 6.60 (s, H-3).
13. 3H-FNZ (81.8 Ci/mmol; NEN) were carried out as described by Levi de Stein, M.; Medina, J. H.; De Robertis, E. Mol. Brain Res. 1985, 5, 9.
14. 14. Ehlert, F. J; Roeske, W. R; Gee, K. W; Yamamura, H. I. Biochem. Pharmacol. 1983, 32, 2375.
15. 15. The animals and the pharmacological test used were as described in reference 4.
16. 16. Medina, J. H.; Viola, H.; Wolfman, C.; Marder, M.; Wasowski, C.; Calvo, D.; Paladini, A. C. Neurochem. Res. 1996, in press.